Steadfast and tenacious in our search for transformative therapies
TARA-002
TARA-002 is the Company’s lead investigational cell therapy based on the broad immunopotentiator OK-432, which is approved in Japan and Taiwan for lymphatic malformations and multiple oncologic indications.
IV Choline Chloride for IFALD
An investigational phospholipid substrate replacement therapy for intestinal failure-associated liver disease (IFALD).
